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Abstract Oncostatin M (OSM) is a potent modulator of human
lung-derived epithelial cell function. This cytokine binds two
distinct receptor complexes: type I OSM receptor which is also a
functional receptor for leukemia inhibitory factor (LIF), and
type II OSM-specific receptor. The role of these two distinct
receptors in mediating the response of individual cell types to
OSM has not been delineated. In contrast to LIF, OSM induces
synthesis of K1-antichymotrypsin and K1-antiproteinase inhibitor
in lung-derived epithelial cells. The differential responsiveness to
LIF and OSM suggested that the response of lung epithelial cells
to OSM may be mediated by the OSM-specific receptor.
Therefore, we characterized lung-derived epithelial cells for the
expression of type II OSM receptor mRNAs, and the regulation
of the mRNAs encoding the components of the OSM-specific
receptor by cytokines and dexamethasone.
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1. Introduction
Oncostatin M (OSM) is a multifunctional cytokine synthe-
sized by hematopoietic cells as well as activated T lympho-
cytes and monocytes [1^3]. OSM is functionally related to the
interleukin-6 family of cytokines, including IL-6, leukemia
inhibitory factor (LIF), IL-11, ciliary neurotrophic factor
and cardiotrophin-1 [4,5]. Members of this family mediate
their biological e¡ects by inducing homodimerization of
gp130 (IL-6, IL-11) or heterodimerization of gp130 and other
signaling (L) receptor subunits (other members). Some of
these cytokines, including IL-6, also require a ligand-binding
subunit that determines receptor speci¢city but is not directly
involved in signaling. Receptor dimerization results in the
activation of cytoplasmic tyrosine kinases followed by the
phosphorylation and nuclear translocation of the STAT fam-
ily of transcription factors [4^6].
Biologically active OSM receptor consists of a heterodimer
of gp130 and LIFRL. This gp130WLIFRL complex, described
as type I OSM receptor, is also a functional receptor for LIF.
Recently, a second OSM-speci¢c receptor complex has been
identi¢ed in the human system, consisting of gp130 heterodi-
merized with an OSM-speci¢c subunit OSMRL, which forms
the type II OSM receptor [7]. Although type I and II OSM
receptors are relatively broadly distributed on a variety of cell
types [7], the role of these two distinct receptors in mediating
the response of individual cell types to OSM has not been
delineated.
In addition to bioactivities shared with other members of
the IL-6 family of cytokines, OSM exhibits some unique ac-
tivities [8]. For example, OSM but not LIF or IL-6 upregu-
lates K1-antichymotrypsin (ACH) and K1-antiproteinase inhib-
itor (K1-PI) levels in lung-derived epithelial cells whereas both
LIF and OSM mediate regulation of both these genes in hep-
atocyte-derived HepG2 cells [9^12]. OSM was found to be one
of the most potent ‘proin£ammatory’ inducers of K1-PI and
ACH synthesis in lung-derived epithelial cells [9^12] and cells
of epithelial origin, including lung epithelium, have been
shown to bind signi¢cant amounts of OSM [13]. Thus the
role of OSM in the lung is of considerable interest. Although
the overlapping spectrum of biological activities of IL-6, OSM
and LIF is well explained [5], much less is known about the
basis for di¡erences in the response to these cytokines. The
speci¢c response to OSM of lung-derived epithelial cells, in-
cluding normal bronchial epithelial cells (NBEC) and two cell
lines, HTB55 and HTB58 (adenocarcinoma and squamous
carcinoma respectively), may indicate the utilization of the
type II OSM receptor. Lung-derived epithelial cells may
thus provide a good model to study potential di¡erences in
the levels of expression of the signaling receptor subunits or
distinct signal transduction pathways, both of which are likely
to account for di¡erences in biological activities between IL-6,
OSM and LIF.
In this study we demonstrate that epithelial cells derived
from lung express type II OSM receptor mRNAs, with OSMRL
levels most likely being more abundant relative to gp130.
Furthermore, we show that the expression of OSMRL and
to a lesser extent gp130 is regulated in these cells by speci¢c
in£ammatory mediators, including OSM.
2. Materials and methods
2.1. Stimulating factors
Human recombinant OSM and human recombinant transforming
growth factor L1 (TGF-L) were purchased from RpD Systems (Min-
neapolis, MN). Human recombinant IL-1L was obtained from Gen-
zyme (Cambridge, MA). Human LIF from conditioned medium of
Chinese hamster ovary cells, containing recombinant LIF at 105 U/ml,
was a generous gift of Dr. H. Baumann (Bu¡alo, NY). Dexametha-
sone (DEX) was purchased from Sigma (St. Louis, MO).
2.2. Cell culture
HTB58 human lung squamous carcinoma, HTB55 human lung ad-
enocarcinoma and HepG2 human hepatoma cell lines were obtained
from the American Type Culture Collection (Rockville, MD). Normal
human bronchial epithelial cells were purchased from Clonetics (San
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Diego, CA). Cells were cultured in Eagle’s MEM (Biowhittaker, Wal-
kersville, MD) supplemented with 0.1 mM non-essential amino acids,
1 mM sodium pyruvate, 100 U/ml penicillin G, 100 Wg/ml streptomy-
cin (all from Gibco, Grand Island, NY) and 10% heat-inactivated
fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA). Bron-
chial cells were cultured in serum-free bronchial epithelial cell basal
medium (Clonetics) containing 0.5 ng/ml human epidermal growth
factor, 5 Wg/ml insulin, 0.5 Wg/ml hydrocortisone and epinephrine,
10 Wg/ml transferrin, 0.5 ng/ml triiodothyronine and 0.4% v/v bovine
pituitary extract (all from Clonetics). Cells were plated, allowed to
grow to con£uency and then treated with various stimulating factors.
2.3. Northern blot analysis
Total RNA was isolated as previously described [14,15]. Northern
blot analysis was carried out by electrophoresis of RNA samples in
1% agarose gels containing 2.2 M formaldehyde, followed by capillary
transfer [16] to Hybond-N membranes (Amersham, Arlington
Heights, IL). Filters were hybridized with the plasmid containing hu-
man OSMRL cDNA (a generous gift of Dr. B. Mosley, Immunex
Corporation, Seattle, WA), human gp130 cDNA (a generous gift of
Dr. T. Kishimoto, Osaka University, Osaka, Japan) and SmaI-BamHI
restriction fragment containing the complete coding sequence of hu-
man LIFRL (a generous gift of Dr. D. Gearing, Immunex Corpora-
tion, Seattle, WA). The probes were labeled using the Megaprime
Labeling Kit (Amersham). The hybridization was carried out at
65‡C in 0.5 M phosphate bu¡er pH 7.0 containing 7% SDS, 1 mM
EDTA, 10 mg/ml BSA and 100 Wg/ml of herring DNA. Non-specif-
ically bound radioactivity was removed by three washes at 65‡C in 40
mM phosphate bu¡er pH 7.0 containing 1% SDS, 1 mM EDTA and
0.5% BSA, followed by three washes at 65‡C in the same bu¡er with-
out BSA. After probing blots were analyzed using a PhosphorImager
(Molecular Dynamics).
3. Results
3.1. Normal bronchial epithelial cells and lung-derived epithelial
cell lines express OSMRL and gp130 mRNA
Northern blot analysis of RNA extracted from lung-derived
epithelial cells revealed signi¢cant levels of OSMRL and
gp130 mRNAs (Fig. 1). The amounts of both transcripts
were compared to that expressed by HepG2 cells. In HepG2
cells which are responsive to IL-6 and to OSM, synthesis of
both gp130 and OSMRL has been reported previously [7]. In
agreement with this study HepG2 were found to express high
levels of OSMRL and gp130 mRNA and the signal was great-
er for OSMRL than for gp130 (Fig. 1, Table 1). In compar-
ison to HepG2 cells, NBEC appeared to express higher
amounts of OSMRL message but less gp130 message (Fig.
1, Table 1). In HTB55 cells levels of both OSMRL and
gp130 mRNAs were lower than in HepG2 cells and the ratio
of OSMRL to gp130 was even greater than in HepG2 cells
(Table 1). A similar ratio of OSMRL to gp130 to that ob-
served in HepG2 cells was noted in HTB58 cells, although in
this case both transcripts were much more abundant (Fig. 1,
Table 1).
3.2. Expression of OSMRL and gp130 in lung-derived epithelial
cells is regulated by cytokines and dexamethasone
Factors which modulate function of lung epithelial cells
were then studied as potential regulators of type II OSM
receptor components in NBEC including, OSM, IL-1 [9^12]
and TGF-L [17]. OSM and TGFL caused signi¢cant increases
in OSMRL mRNA levels ; IL-1, however, had no e¡ect (Fig.
2). OSM was also e¡ective in upregulating gp130 mRNA
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Fig. 1. Comparison of OSMRL and gp130 mRNA levels in NBEC,
HTB55, HTB58 and HepG2 cells. Aliquots of total RNA (5 Wg) iso-
lated from the indicated cell types were resolved by gel electrophore-
sis, transferred to a nylon membrane, and the ethidium bromide-im-
pregnated blot was photographed to demonstrate comparable
loading (bands of 28S rRNA and 18S rRNA are indicated). The
blot was then hybridized with 32P-labeled gp130 and OSMRL
probes. The blot is representative of three independent experiments.
Table 1
Relative quantitation of OSMRL and gp130 mRNA levels in lung-
derived epithelial cells
OSMRL gp130 OSMRL/gp130
NBEC 28.5 10.1 2.8
HTB58 53.9 36.6 1.5
HTB55 19.8 4.3 4.6
HepG2 26.5 16.5 1.6
The Northern blot presented in Fig. 1 was exposed to a Phosphor-
Imager screen, and the resulting image was scanned. Arbitrary num-
bers indicate the relative amounts of OSMRL- and gp130-speci¢c
mRNAs in NBEC, HTB58, HTB55 and HepG2 cells.
Fig. 2. Regulation of expression of the type II OSM receptor com-
ponents in NBEC. Cells were incubated for 24 h with 50 ng/ml
OSM, 5 U/ml IL-1 or 10 ng/ml TGFL. Total RNA was then iso-
lated and subjected to Northern blot analysis. Similar amounts of
ethidium bromide-stained 28S and 18S rRNA are visualized in the
bottom panel. In the upper panel the positions of the gp130- and
OSMRL-speci¢c bands are indicated. The blot is representative of
three independent experiments.
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levels, whereas both TGFL and IL-1 reduced the amount of
gp130 transcripts.
In order to compare the regulation of OSMR in NBEC to
other lung-derived epithelial cells which expressed di¡erent
ratios of OSMRL to gp130 mRNA, we extended our study
to HTB58 and HTB55 cells. Treatment of both cell types with
OSM led to stimulation of OSMRL and gp130 expression,
although in the case of HTB55 cells the e¡ect of OSM was
more evident in the presence of the glucocorticoid analog
dexamethasone (DEX), a factor capable of intensifying the
e¡ect of cytokines on these cells [9^12]. DEX given alone
signi¢cantly upregulated gp130 levels in HTB58 cells. When
given in combination with cytokines, DEX generally increased
the levels of gp130 mRNA and, to a lesser extent, OSMRL
mRNA in both cell types. IL-1 alone appeared not to a¡ect
the expression of OSMR but given in combination with OSM,
or more markedly OSM and DEX, IL-1 further enhanced the
upregulation of the mRNA levels for both components of the
receptor in HTB58 and HTB55 cells. In contrast, the e¡ect of
TGFL was found to be cell-speci¢c. TGFL generally acted as
a negative regulator of OSMR expression in HTB58 cells and
as a stimulator in HTB55 cells. Interestingly, in the HTB58
cells, the most substantial increase in OSMRL and gp130
mRNA levels was noted when the cells were treated with a
combination of TGFL, OSM and DEX.
3.3. OSM and LIF exert di¡erent e¡ects on expression of type
I and II receptors
Since OSM signi¢cantly increased type II OSM receptor
levels it was interesting to determine if it had any e¡ect on
LIFRL and ultimately type I receptor. We found that treat-
ment with OSM caused a reduction in the levels of LIFRL
transcripts in HTB58 cells (Fig. 3). We previously demon-
strated that HTB58 cells have the potential to utilize type I
receptor since LIF treatment induced tyrosine phosphoryla-
tion of gp130 and LIFRL [12].
We therefore examined the e¡ect of LIF on type I and II
receptors in these cells. In the presence of DEX, LIF similarly
to OSM, stimulated OSMRL and to a lesser extent gp130
mRNA levels, but, in contrast to OSM, did not reduce LIFRL
mRNA levels (Fig. 4). The increase in OSMRL and gp130
levels by LIF was also observed in NBEC (data not shown).
4. Discussion
Many of the overlapping biological e¡ects of IL-6 related
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Fig. 3. Regulation of gp130 and OSMRL mRNA levels in HTB58 and HTB55 cells. Cells were incubated for 24 h with 50 ng/ml OSM, 5 U/ml
IL-1, 10 ng/ml TGFL and/or 1036 M DEX. The levels of gp130 and OSMRL were then determined by Northern blot analysis. The blot was
photographed to demonstrate equal loading (bands of 28S RNA and 18S rRNA are shown) and then hybridized to 32P-labeled gp130 and
OSMRL probes. The blots are representative of three independent experiments.
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cytokines can be attributed to the presence of a common
receptor subunit, gp130, or in the case of OSM and LIF, to
binding of the same receptor consisting of two components,
gp130 and LIFRL [5]. However, signi¢cant functional di¡er-
ences between LIF and OSM have also been described and,
some cell types are incapable of binding LIF in spite of ex-
pressing high a⁄nity functional OSM receptors [8]. Taken
together, these ¢ndings suggested the existence of an OSM-
speci¢c receptor. Recently, an alternative subunit, OSMRL, of
an OSM receptor complex was cloned [7]. This subunit asso-
ciates with the low a⁄nity OSMWgp130 complex to form a
high a⁄nity heterodimeric receptor that is capable of trans-
ducing OSM-speci¢c signaling events. Although the signal
transduction pathways that mediate OSM-speci¢c responses
have not yet been fully delineated, OSM can activate path-
ways linked to MAP kinase [8], src-related kinases [18] and
more notably a JAK-STAT pathway that includes STAT3,
STAT1 and STAT5 [5,19,20]. Interestingly, activation of
STAT5 has been reported to be mediated by the type II
OSM receptor [19]. The biological activities of OSM, some
of which are OSM-speci¢c and some of which are shared by
LIF, can be explained by utilization of a dual receptor system.
However, although a dual receptor system is evident in the
human system, in mice OSM apparently utilizes only its spe-
ci¢c receptor complex [21].
We previously demonstrated in the human system that sev-
eral genes are speci¢cally regulated by OSM but not other
members of the IL-6 family of cytokines [9^12]. Our under-
standing of the speci¢city of the response to OSM and LIF
will depend on identifying the role of the two potential recep-
tors in mediating these responses. There are several major
¢ndings in this study: (i) lung-derived epithelial cells express
both subunits of type II OSM receptor, i.e. gp130 and OSMRL,
(ii) OSMRL mRNA levels appeared to be higher than gp130
in these cells, suggesting that the levels of gp130 may be the
limiting factor in the formation of the type I and type II
receptors, (iii) there is no consistent di¡erence in the ratio
of OSMRL to gp130 between HepG2 (responsive to OSM,
LIF and IL-6) and lung-derived epithelial cells (responsive
only to OSM), (iv) OSMRL and gp130 mRNA levels are
regulated by speci¢c mediators, (v) type II receptor is upregu-
lated by either OSM or LIF whereas type I receptor is down-
regulated by OSM in HTB58 cells. The expression of OSMRL
and gp130 in all lung-derived epithelial cell types examined
indicates that the type II OSM-speci¢c receptor may mediate
the e¡ects of OSM on lung-derived epithelial cells. Further-
more, based on the high ratio of OSMRL mRNA relative to
gp130 mRNA levels, it is likely that there is an excess of OSMRL
produced that can successfully compete to form dimers with
the gp130 subunit even if the gp130 is expressed in limited
amounts and in the presence of LIFRL.
The expression of OSM type II receptor in lung-derived
epithelial cells was found to be regulated by cytokines, of
which OSM was the most potent stimulator. The cytokines
that regulated the steady state mRNA levels of the compo-
nents of the OSM type II receptor are produced by activated
monocytes and T cells and can be produced by in¢ltrating
cells at sites of in£ammation. Importantly, lung-derived epi-
thelial cells are stimulated by OSM and IL-1 for the produc-
tion of serine proteinase inhibitors, proteins which have been
postulated to prevent tissue damage associated with in£am-
mation [9^12]. The additive e¡ects of OSM and IL-1 on syn-
thesis of these inhibitors can be explained by the present study
showing the role of both cytokines in upregulation of OSMR
expression. Moreover, since TGFL was also found to regulate
OSMR levels it may also act as a modulator of OSM e¡ects in
lung-derived epithelial cells. However, such a role of TGFL
remains to be determined.
The ¢nding that LIF was capable of modulating type II
receptor levels in HTB58 and NBEC further supports the
concept that the inability of LIF to induce K1-PI and ACH
synthesis in these cells is not due to the lack of functional type
I receptors. Di¡erent e¡ects of OSM and LIF resulting in
downregulation of LIFRLby OSM and upregulation of OSMRL
by both cytokines may suggest that in the presence of both
OSM and LIF preference will be given to OSM due to the
preferential increase in type II OSM receptors.
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